Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
CD137 promotes proliferation and survival of human B cellsXiaoyu Zhang, Caroline J Voskens, Michelle Sallin, et al.
Frontiers in Immunology|October 27, 2018
IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During Trypanosoma cruzi InfectionJimena Tosello Boari, Cintia L Araujo Furlan, Facundo Fiocca Vernengo, et al.
British Journal of Cancer|July 16, 2009
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumoursK Jacob, S Albrecht, C Sollier, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 19, 2017
Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected PatientsRocio Montejano, Natalia Stella-Ascariz, Susana Monge, et al.
Oncoimmunology|October 9, 2023
Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cellsConstanza Rodriguez, Cintia L Araujo Furlan, Jimena Tosello Boari, et al.
AIDS (London, England)|July 12, 2012
Transient elastography to rule out esophageal varices and portal hypertensive gastropathy in HIV-infected individuals with liver cirrhosisMaria L Montes Ramirez, Jose F Pascual-Pareja, Matilde Sánchez-Conde, et al.
Cancer Research|October 26, 2017
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T CellsFernando P Canale, María C Ramello, Nicolás Núñez, et al.
HIV Medicine|April 5, 2023
Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119R Palacios, C Gómez-Ayerbe, J L Casado, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 8, 2009
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysisJose R Arribas, Rafael Delgado, Alberto Arranz, et al.
Frontiers in Immunology|February 11, 2026
Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progressionCarolina Abrate, Valentina Brunotto, Sabrina N Bossio, et al.
Pageof 16